Related Experiment Video
Updated: Mar 8, 2026

Rapid Depletion of Renal Macrophages Using Human CD59/Intermedilysin Cell Ablation Tool
Published on: May 9, 2025
Rationale for the milvexian dosing in the phase 3 LIBREXIA program
Jeffrey I Weitz1, Robert A Harrington2,
1Departments of Medicine and Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada; Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada; Hamilton Health Sciences, Hamilton, Ontario, Canada.
Background:
Milvexian is an oral, small-molecule inhibitor of factor (F)XIa undergoing evaluation in phase 3 clinical trials.
Objectives:
This manuscript aimed to explain the rationale underpinning the hypothesis that FXIa may be a safer target for anticoagulants than FXa; describe the pharmacology of milvexian; review the results of the phase 2 trials with milvexian; and detail how the phase 2 program informed the dosing regimens for the phase 3 trials.
Methods:
This narrative review addresses the above objectives with the primary focus on addressing how the milvexian dosing regimens were selected for the phase 3 LIBREXIA program, which compares milvexian with apixaban for atrial fibrillation (AF) in the LIBREXIA AF trial (NCT05757869) and with placebo, in addition to background single or dual antiplatelet therapy, in patients with acute coronary syndrome (ACS) in the LIBREXIA ACS trial (NCT05754957), and for noncardioembolic ischemic stroke and high-risk transient ischemic attack in the LIBREXIA Stroke trial (NCT05702034).
Results:
The milvexian dose regimen selected for the LIBREXIA AF trial is 100 mg twice daily, and for the LIBREXIA ACS and Stroke trials, it is 25 mg twice daily.
Conclusions:
The phase 3 LIBREXIA program will determine whether these dose regimens afford safe and effective anticoagulation in approximately 50 000 patients with AF, ACS, or prior stroke.
More Related Videos
09:12MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells
Published on: December 21, 2011
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
Related Concept Videos
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Rational Dosage Regimen: Maintenance Dose and Loading Dose
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Dosage Regimens: Partial Pharmacokinetic Parameters
Dosage Regimen: Individualization